Silo Pharma welcomes federal psychedelic actions, touts SPC-15 PTSD candidate

Silo Pharma, Inc. (SILO) — Silo Pharma issued a statement welcoming a wave of coordinated U.S. federal actions accelerating psychedelic research, including ARPA-H EVIDENT awards, the FDA's issuance of three National Priority Vouchers and an IND clearance for DemeRx NB.

The company highlighted its intranasal PTSD candidate SPC-15 as positioned to benefit from renewed federal focus following the April 18 executive order. Silo framed the policy shift as supportive of its preclinical-to-clinical development plans.

Source: stocktitan.net

For the rest of that week's sector news, read our week in review.